|Assessment Status||Rapid Review Complete|
|Indication||For the treatment of adult patients with Cushing’s Disease for whom surgery is not an option or for whom surgery has failed|
|Rapid review commissioned||29/03/2012|
|Rapid review completed||10/04/2012|
|Rapid review outcome||Full Pharmacoeconomic Assessment Recommended|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.